compound tirzepatide shortage Impurity in Some Compounded 'Potentially Dangerous,' Eli Lilly Warns led and built for women Eli Lilly's Weight-Loss Drug Zepbound

Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026

This is either liberation or the first fifteen minutes of a disaster movie where everyones laughing at brunch and the audience is screaming WHY IS NOBODY READING THE LABEL at their screens

Reaching a goal weight does not mean the metabolic adaptations that caused weight gain in the first place have resolved

Targeting oxidative stress in disease: promise and limitations of antioxidant therapy